Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04770155 · ClinicalTrials.gov registry record · Early Phase 1
Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1
A Early Phase 1 study, sponsored by University of Mississippi Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT04770155 is a Early Phase 1 study that was terminated before completion, run by University of Mississippi Medical Center. The registered enrollment target is 8 participants.
The verdict
NCT04770155, a Early Phase 1 study, was terminated before completion, sponsored by University of Mississippi Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The research aims of this proposal are: * Specific Aim 1: To test whether an increase in nitric oxide signaling can increase vasodilator responses in young Black individuals. * Specific Aim 2: To test whether a decrease in endothelin-1 signaling can increase vasodilator responses in young Black individuals.
Interventions
- DRUG Sildenafil 100 mg
- DIETARY_SUPPLEMENT Dietary Nitrates 400 mg
- DIETARY_SUPPLEMENT L-citrulline 3 g
- DRUG Bosentan 125 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2021-09-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04770155
The ClinicalTrials.gov registry entry for NCT04770155 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sildenafil 100 mg is the first listed.
NCT04770155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04770155 about?
NCT04770155 is a clinical study titled "Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1". The research aims of this proposal are: * Specific Aim 1: To test whether an increase in nitric oxide signaling can increase vasodilator responses in young Black individuals. * Specific Aim 2: To test whether a decrease in endothelin-1 signaling can increase vasodilator responses in young Black ind...
What is the current status of trial NCT04770155?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2021-05-27. Estimated completion is 2021-09-20.
What interventions are being tested in trial NCT04770155?
The interventions under investigation include: Sildenafil 100 mg (DRUG), Dietary Nitrates 400 mg (DIETARY_SUPPLEMENT), L-citrulline 3 g (DIETARY_SUPPLEMENT), Bosentan 125 mg (DRUG).
Who is sponsoring clinical trial NCT04770155?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.